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  24 
Abstract 25 
Oral consumption of inorganic nitrate, which is abundant in green leafy 26 
vegetables and roots, has been shown to increase circulating plasma nitrite 27 
concentration, which can be converted to NO in low oxygen conditions.  The 28 
associated beneficial physiological effects include a reduction in blood pressure, 29 
modification of platelet aggregation and increases in limb blood flow. 30 
There have been numerous studies of nitrate supplementation in healthy 31 
recreational and competitive athletes, however, the ergogenic benefits are currently 32 
unclear due to a variety of factors including small sample sizes, different dosing 33 
regimens, variable nitrate conversion rates, the heterogeneity of participants’ initial 34 
fitness levels and the types of exercise tests employed.  In clinical populations, the 35 
study results seem more promising, particularly in patients with cardiovascular 36 
diseases who typically present with disruptions in the ability to transport oxygen from 37 
the atmosphere to working tissues and reduced exercise tolerance. Many of these 38 
disease-related, physiological maladaptations including, endothelial dysfunction, 39 
increased reactive oxygen species, reduced tissue perfusion and muscle 40 
mitochondrial dysfunction have been previously identified as potential targets for NO 41 
restorative effects. 42 
This review is the first of its kind to outline the current evidence for inorganic 43 
nitrate supplementation as a therapeutic intervention to restore exercise tolerance 44 
and improve quality of life in patients with cardiovascular diseases.  We summarise 45 
the factors that appear to limit or maximize its effectiveness and present a case for 46 
why it may be more effective in patients with CVD than as ergogenic aid in healthy 47 
populations.  48 
 49 
50 
Introduction 51 
Nitric oxide (NO) is a diatomic, lipid-soluble gas, implicated in numerous 52 
physiological functions including neurotransmission, immune defence, blood flow 53 
regulation, among others.  In the presence of oxygen, NO is produced by the 54 
vascular endothelium via the oxidation of L-arginine to NO and L-citrulline by 55 
endothelial NO-synthase (2).  NO bioavailability is a balance between its rate of 56 
production and subsequent rate of consumption via various biological signaling 57 
pathways and chemical reactions.  Vascular NO bioavailability has been shown to be 58 
essential for cardiovascular health and a reduction in the ability to produce NO by 59 
the vascular endothelium is an early event in the process of atherosclerotic lesion 60 
formation and is associated with cardiovascular risk factors (41, 42, 218), diabetes 61 
(50) and established cardiovascular disease (155).  This dysfunctional endothelium 62 
limits eNOS-dependant therapeutic strategies to increase vascular NO 63 
bioavailability, and approaches utilizing NO-donor compounds have been limited in 64 
their clinical applications primarily due to their systemic vascular effects often 65 
resulting in hypotension.  66 
The short half-life of NO makes it difficult to measure directly in vivo human 67 
models, but its expression has previously been shown to be directly proportional to 68 
plasma nitrite levels(4, 179), suggesting nitrite may be a measurable reflection of 69 
vascular NO bioavailability.  Despite decades long knowledge that nitrite acts as a 70 
vasodilator at supra-physiological (micromolar) concentrations(70), it was regarded 71 
within biological systems as an inactive “NO-sink,” which was ultimately excreted by 72 
the kidneys.  Recently, nitrite (along with S-nitrosothiols(213), N-nitroso proteins and 73 
iron-nitrosyl complexes(178)) have been shown to be reduced back to NO under 74 
hypoxic conditions (134).  This indicates a discrete yet complimentary system to 75 
oxygen-dependant eNOS production, which may enable vascular NO bioavailability 76 
across the oxygen gradient.  Furthermore, it suggests conservation of NO and an 77 
endocrine-like function where delivery via plasma nitrite may target specific tissues 78 
with low oxygen concentrations.  Consequently, mechanisms to increase plasma 79 
nitrite may be particularly useful in conditions associated with tissue ischemia, 80 
including some cardiovascular diseases pathologies and specifically during a 81 
physiological challenge requiring an upregulation in tissue perfusion such as 82 
exercise. 83 
 84 
Inorganic Nitrate Supplementation to Increase Plasma Nitrite 85 
Inorganic nitrate supplementation has been shown to be a simple, non-86 
invasive means of exogenously increasing plasma nitrite concentration and, 87 
consequently, NO bioavailability(132, 133).  Inorganic nitrate is found in relatively 88 
high concentrations, approximately 250mg per 100g, in green leafy vegetables such 89 
as kale, cabbage, lettuce, rocket, spinach, and beetroot(95). It is important to note 90 
that the exact NO3- content of these vegetable sources can vary depending on 91 
growth environment, geographical location and how they are treated(194). 92 
Oral supplementation with inorganic nitrate works in a two-step process 93 
(Figure 1) whereby following consumption, nitrate is rapidly absorbed in the small 94 
intestine and enters circulation. While a majority (~75%) is subsequently excreted by 95 
the kidneys, approximately 25% becomes highly concentrated in the salivary glands 96 
(up to 10 times the plasma concentration)(211). When this nitrate is released from 97 
the salivary glands, commensal oral bacterial on the dorsal surface of the tongue 98 
reduces nitrate to nitrite(60).  The nitrite is then swallowed and absorbed into 99 
circulation via the intestinal tract(23, 135). Due to this two-pass process, plasma 100 
nitrite concentrations take approximately 2.5 to 3 hours to reach maximal levels 101 
(200 to 400nM), following a single dose of inorganic nitrate.  The half-life of nitrite 102 
appears to be approximately 6 hours(100, 143, 146, 233, 244). Chronic nitrate 103 
supplementation can maintain elevated nitrite levels continuously and helps to avoid 104 
the short-lived bolus effects of direct oral nitrite administration (228, 245). 105 
The circulating plasma nitrite can then undergo one-electron reduction to NO 106 
by numerous nitrite-reductases including deoxyhemoglobin(54), 107 
deoxymyoglobin(204), mitochondrial enzymes(157) and chemical acidification(249).  108 
In this way, inorganic nitrate acts as a targeted supplement, whereby the resulting 109 
nitrite is reduced to NO in tissues with a low partial pressure of oxygen (PO2) which 110 
may facilitate better overall distribution of the available blood flow and allow for 111 
greater oxygen extraction in those with cardiovascular disease (CVD) but also during 112 
exercise stress. 113 
 114 
Inorganic Nitrate Supplementation in Cardiovascular Disease 115 
Several pharmacological agents for CVD enhance NO signalling either via 116 
increasing bioavailability or inhibiting NO breakdown.  The most obvious of these is 117 
organic nitrate (eg. glyceryl trinitrate) which acts via the rapid release of NO causing 118 
nonspecific arterial and venodilation and is subject to the development of tolerance.  119 
Another type is phosphodiesterase-5-inhibitors which are used in patients with 120 
erectile dysfunction and pulmonary hypertension(72).  In addition, HMG-CoA 121 
reductase inhibitors (statins) and angiotensin-converting enzyme inhibitors/receptor 122 
blockers indirectly increase NO bioavailability(162). 123 
Currently several countries recommend dietary interventions high in inorganic 124 
nitrate for patients with cardiovascular conditions.  For example, the Dietary 125 
Approaches to Stop Hypertension (DASH) dietary pattern(10, 192), which 126 
emphasizes fruits, vegetables and low-fat dairy foods, and includes whole grains, 127 
poultry, fish, and nuts can potentially contain up to 20mmol of inorganic nitrate per 128 
day(95).  It is recommended by The National Heart, Lung and Blood Institute(196), 129 
The American Heart Association(11), the American Diabetes Association(21), and 130 
the Dietary Guidelines for Americans(227).  High dietary inorganic nitrate intake has 131 
been shown to decrease blood pressure(71, 112), and lower the risk for heart 132 
disease(108) and stroke(107). 133 
The most consistent applied clinical outcome from increased oral inorganic 134 
nitrate intake is a reduction in blood pressure.  In 2006, 3 days of sodium nitrate 135 
administration (0.1mmol/day) was shown to reduce diastolic blood pressure (DBP) 136 
by 3.7mmHg in healthy volunteers(128).  In 2008, Webb et al., demonstrated an 137 
acute dose of 22.5mmol inorganic nitrate via beetroot juice (500ml) reduced systolic 138 
blood pressure (SBP) and DBP by ≈10 and 8mmHg respectively(233).  Furthermore, 139 
the drop in blood pressure was correlated to plasma nitrite concentrations and both 140 
changes could be abolished by interruption of the enterosalivary conversion of nitrate 141 
to nitrite.  Since this study, similar benefits have been observed in studies of patients 142 
with hypertension(73). A double-blind placebo controlled study where 68 patients 143 
were given a 6mmol dose of inorganic nitrate, via 250ml beetroot juice, for 4 weeks, 144 
demonstrated significant reductions in clinic measured (≈8/2.5mmHg), 24-hour 145 
ambulatory (≈8/5mmHg), and home measured (≈8/4mmHg) blood pressures(112).  146 
These reductions are clinically significant when it is considered that a 1mmHg 147 
increase in SBP is estimated to increase cerebrovascular incident mortality by 2% 148 
and a 1 mmHg increase in DBP may increase stroke mortality by 3%(162, 165). 149 
Other documented benefits for CVD include increased endothelial function, 150 
(86, 126), reduced tissue loss following an myocardial infarction(38, 209) reduced 151 
platelet aggregation(184, 233), and attenuation of pulmonary hypertension(96).  152 
Recently, Bondonno et al.(25),  showed that, after adjusting for other cardiovascular 153 
risk factors and lifestyle components, a higher dietary vegetable nitrate intake over a 154 
period of 14 years was associated with a lower carotid artery intimal-medial 155 
thickness and a lower risk of an ischemic cerebrovascular disease events in 1226 156 
elderly women.  Excellent reviews of other benefits of increased dietary inorganic 157 
nitrate supplementation for cardiovascular and metabolic health have been published 158 
previously(162, 181, 234). 159 
 160 
Inorganic Oral Nitrate Supplementation and Exercise 161 
During resting conditions, peripheral skeletal muscle tissues are usually 162 
adequately perfused, however, during exercise stress the increased metabolic 163 
demands of skeletal muscles can outstrip the ability to supply blood flow and oxygen 164 
causing a decline in pH and inter-myocyte and microvascular oxygen tensions(67, 165 
185, 219).  Given that nitrite is reduced in low oxygen and acidic conditions, this 166 
environment may be ideal to liberate NO and contribute to optimal matching of 167 
perfusion to metabolic demands. 168 
In support of this theory, intravascular consumption of nitrite during physiological 169 
stress in humans was first reported by Gladwin et al., in 2000.  They showed artery 170 
to venous nitrite gradients in the forearm of healthy subjects during L-NMMA infusion 171 
coupled with handgrip exercise(75).  Similarly, our data in subjects with peripheral 172 
arterial disease (PAD) and documented endothelial dysfunction showed a net loss of 173 
plasma nitrite stores following maximal exercise stress.  This was in comparison to 174 
healthier counterparts with a functioning endothelium(3, 7).These studies allow us to 175 
speculate that, in the setting of a depleted or inhibited endogenous source of 176 
vascular NO during exercise-induced tissue ischemia, there is the potential for 177 
significant decrease in the circulating nitrite/NO pool, potentially in an attempt to 178 
normalize blood flow and oxygen delivery to hypoxic tissues. 179 
In addition to increasing tissue perfusion, NO has been shown to have a 180 
variety of potential physiological benefits in exercising skeletal muscle beds (as 181 
outlined below) which may contribute to increasing exercise performance.  They also 182 
suggest the ergogenic benefit of consuming inorganic nitrate may be optimal under 183 
conditions where the cardiorespiratory and musculoskeletal systems are close to or 184 
exceed their maximal capacity to transport oxygen from the lungs to the working 185 
myocyte. 186 
In this review, we will outline the evidence for inorganic nitrate 187 
supplementation as an ergogenic aid and summarise the factors that appear to limit 188 
or maximize its effectiveness.  We will present evidence that suggests inorganic 189 
nitrate supplementation offers a greater opportunity as a therapeutic intervention to 190 
partially restore exercise tolerance and improve quality of life in patients with 191 
cardiovascular diseases than as an ergogenic aid in healthy populations. 192 
 193 
Inorganic Nitrate Supplementation and Exercise Performance in Healthy Subjects 194 
The main physiological parameters during exercise that are documented to be 195 
influenced by inorganic nitrate supplementation include mitochondrial function(110, 196 
148, 204), skeletal muscle contractile efficiency(18, 48, 81), and tissue 197 
perfusion/oxygen delivery(19, 66, 67, 113, 141).   198 
 199 
a) Changes in Mitochondrial Function 200 
A period of intense interest in the role of dietary inorganic nitrate as a potential 201 
ergogenic aid was initiated in 2007 by Larsen and colleagues’ discovery that 3 days 202 
of dietary sodium nitrate supplementation resulted in a reduction in oxygen cost 203 
during submaximal cycling(130).  These changes were observed following a 204 
relatively small dose of nitrate (0.1mmol kg-1 bodyweight day-1) likened to that which 205 
is readily available from everyday dietary sources (150-250g of green leafy 206 
vegetables)(132).   207 
Prior to Larsen’s discovery, the prevailing dogma was that oxygen cost 208 
(ml/kg/min) during sub-maximal exercise at a particular workload was fixed, with 209 
responses being almost identical within and between subjects(174).  While it was 210 
understood that individuals with a period of training could become mechanically 211 
more efficient, the subjects in Larsen’s study had no differences in training status, 212 
heart rate, or blood lactate between tests.  They appeared to have become more 213 
efficient via changes in mitochondrial function. 214 
In a follow-up study, the group investigated the effects of nitrate 215 
supplementation on maximal aerobic exercise capacity (VO2max) during combined 216 
upper and lower body exercise. The results showed that nitrate supplementation 217 
resulted in a lower VO2max but an increased time to exhaustion(129). This occurred 218 
without changes in anaerobic energy consumption (measured by maximal 219 
ventilation), respiratory exchange ratio, blood lactate levels, or heart rate.  They 220 
suggested that this may be due to not only improved muscular efficiency but a 221 
corresponding reduction in mitochondrial proton leakage(129). Further elucidating 222 
the potential mechanisms of dietary nitrate on exercise economy, Larsen showed 223 
that reductions in whole body VO2 occurred simultaneously with increased oxidative 224 
phosphorylation efficiency(127).   225 
Others have shown that nitrite and NO signalling can affect mitochondrial 226 
function at several key steps in order to potentially match respiration to oxygen 227 
availability(22, 204-206).  For example, during low oxygen conditions, nitrite has 228 
been shown to inhibit Complex I (NADH Coenzyme Q oxidoreductase) by S-229 
nitrosylation leading to decreased mitochondrial reactive oxygen species (ROS) 230 
generation.  Similarly, the reduction of nitrite to NO (potentially via deoxymyoglobin 231 
or xanthine oxidase) has been shown to specifically and reversibly inhibit 232 
cytochrome oxidase (complex IV)(34).  In addition, peroxynitrite (ONOO-) may inhibit 233 
multiple respiratory complexes under specific conditions(34).  When oxygen 234 
availability is restored, these inhibitory mechanisms are reversed (NO is oxidized to 235 
nitrite) to resume ATP production, while inhibition of complex I is prolonged to limit 236 
ROS production(206).  These mechanisms have also been implicated in nitrite 237 
mediated cytoprotection following ischemia/reperfusion injury(87, 206, 232).  238 
Interestingly, studies that have employed an NO-blockade approach to measure its 239 
effects on changes in skeletal muscle mitochondrial function and oxygen uptake in 240 
humans have been mainly negative(195).  This may be due to multiple integrated or 241 
redundant mechanisms employed in intact model physiology(226) or potentially 242 
multiple nitration and nitrosylation signalling pathways initiated by exogenous 243 
administration of NO species (as described above).  It may even be a function of the 244 
technology used to take measurements. Recently Heinonen et al.(84), using positron 245 
emission tomography and radiolabelled water, showed that NO blockade enhanced 246 
resting oxygen uptake and when combined with cyclooxygenase (COX) inhibition 247 
muscle oxygen uptake also increased during exercise. 248 
 249 
b) Changes in Skeletal muscle contractile efficiency 250 
A second major area in which inorganic nitrate supplementation may increase 251 
exercise performance is via changes in neuromuscular contractile efficiency.  In 252 
2010, Bailey et al. demonstrated a reduced oxygen cost of exercise following dietary 253 
nitrate, which they attributed to a reduced ATP turnover in the contracting myocytes 254 
which can influence the stimulus for oxidative metabolism.  Similarly, the sparing of 255 
PCr was associated with improved exercise tolerance in high intensity exercise(18).  256 
Others have shown increased maximal knee extensor speed and power in voluntary 257 
(48, 49, 187, 236) and stimulated muscle contractions(81).  These benefits have 258 
been attributed to increases in NO led activation of sGC, cGMP and subsequent 259 
phosphorylation of myosin(139), although others showed no changes in redox status 260 
and calcium handling proteins(236). 261 
 262 
c) Changes in Skeletal muscle tissue perfusion/oxygen delivery 263 
A third major mechanism of action of inorganic nitrate supplementation is 264 
improving skeletal muscle tissue perfusion.  Oxygen supply to myocytes is a balance 265 
between blood flow delivery and oxygen extraction.  It is essential that perfusion is 266 
optimised to the muscle fibers that are actively contracting.  Microvascular PO2 267 
represents the dynamic balance between oxygen supply and myocyte consumption.  268 
An increase in PO2 suggests enhanced blood flow (supply) and potentially increased 269 
mitochondrial and contractile efficiency during exercise. 270 
Infusion of the vasodilator ATP into the leg at near-maximal intensities of 271 
exercise has been shown to increase vascular conductance but not limb VO2(37).  272 
This suggests a concomitant decrease in arterial-venous oxygen extraction which 273 
may be caused by some of the increased blood flow directed to less-active fibers 274 
(that may normally be under a vasoconstrictive influence)(85).  Given that nitrite is 275 
reduced to liberate NO in low oxygen and acidic conditions, this system may 276 
contribute to optimal matching of perfusion to metabolic demands and allow for 277 
greater oxygen extraction.   278 
Neuronal-NOS (nNOS) is located beneath the sarcolemma of skeletal muscle 279 
fibers and is associated with the dystrophin-g1 ycoprotein complex.  It has been 280 
suggested that the greater distribution of nNOS to type II fibers(177) may play a role 281 
in the differential fiber type responses.  When healthy skeletal muscle is exercised 282 
nNOSμ-derived NO attenuates α-adrenergic vasoconstriction, thus optimizing 283 
perfusion(220).  During high intensity exercise in rats, there are reductions in blood 284 
flow and vascular conductance and the greatest occur in type II fibers. However, no 285 
changes were observed during low-intensity running(52). Humans with Becker 286 
muscular dystrophy lack sarcolemma nNOS, and have been shown to have 287 
functional muscle ischemia which was relieved by a single dose of oral sodium 288 
nitrate.  There was no effect on healthy controls(156).  In addition, the lower levels of 289 
antioxidant enzymes in type II muscle fibers in comparison to type I fibers(102) 290 
suggest that during high intensity activity, exogenous NO bioavailability within the 291 
muscle may also benefit NO-mediated calcium signalling and mitochondrial function 292 
as outlined above.  293 
 In support of these ideas, in animal models, dietary inorganic nitrite 294 
supplementation (via beetroot juice) increased exercise skeletal muscle blood flow 295 
predominantly to type II fibers(65).  Subsequent studies by the same group showed 296 
nitrate supplementation increased the microvascular and myocyte PO2 only in type 297 
IIx/d fibers compared to control(67).  In humans, the data is less clear.  A recent 298 
study employing NOS-inhibition and PET scanning, failed to show differences in 299 
blood flow between the different muscles that make up the quadriceps femoris; 300 
vastus intermedius (VI), rectus femoris (RF), vastus medialis (VM), and vastus 301 
lateralis (VL)(83).  Similarly, Breese et al., using near infra-red spectroscopy saw no 302 
differences in the spatial variance of absolute deoxyhemoglobin+myoglobin kinetics 303 
across the RF, VL and VM muscles following the onset of heavy step cycling(32).   304 
Differences between these human results and those of rat studies are likely 305 
attributable to the fact that only one exercise intensity was used and that human 306 
muscles have less spatial stratification of muscle fibre types than rodents.  Future 307 
human studies may be best served by utilizing several different intensities of 308 
workload and investigating the musculature of the calf, which has more distinct fibre 309 
types in its muscle parts. 310 
A further physiological mechanism to suggest benefits from dietary inorganic 311 
nitrate on fast twitch skeletal muscle fibers is increases in contractile force.  While 312 
the process is not currently fully elucidated, it is clear NO plays a role in skeletal 313 
muscle calcium flux via S-nitrosylation of ryanodine receptor Ca2+ release channels 314 
in the sarcoplasmic reticulum membrane and that this occurs only at low 315 
physiological PO2 levels.  Following 7 days of inorganic nitrate supplementation in 316 
rats, Hernandez et al.(89), showed an increased rate of muscle force development in 317 
the predominantly fast twitch extensor digitorum longus muscle (but not the 318 
predominantly slow twitch soleus).  This was accompanied by changes in protein 319 
concentrations of the voltage-sensing dihydropyridine receptor (voltage sensor for 320 
excitation coupling located in the transverse tubular membrane) and the calcium 321 
handling protein calsequestrin 1, found in sarcoplasmic reticulum of fast–twitch 322 
fibers.  In humans, however, despite improvements in skeletal muscle contractile 323 
function, there we no changes in calcium handling proteins(236).  The muscle 324 
samples taken in this study were from the vastus lateralis, which is estimated to be 325 
composed of ~50% type I and ~50% type II fibres and may have contributed to a 326 
dilution of potential differences.  327 
In terms of human exercise performance, the preferential effects of dietary 328 
inorganic nitrate on fast twitch muscle fibers suggests ergogenic effects may be most 329 
evident in activities of high intensity and short duration, such as sprint or interval 330 
training. During these short, high-intensity efforts (at greater than 75% VO2Max) there 331 
is an increased activation of type II muscle fibers(231). Bailey et al., showed that 332 
short-term beetroot juice supplementation can increase muscle oxygenation, 333 
expedite the adjustment of oxidative metabolism, and enhance exercise tolerance in 334 
healthy recreationally active subjects when cycling at high-intensities(19, 20).  There 335 
are also several examples that support the fiber-type specific responses in relation to 336 
better tissue muscular power/force generation in repeated sprint activities and team 337 
sports(15, 48, 81, 175, 187, 242, 243). Following an acute dose of inorganic nitrate 338 
supplementation (11.1mmol) collegiate athletes were able to increase their 339 
maximum power output (pre-nitrate: 1160 ± 301W post-nitrate: 1229 ± 317 340 
=W)(187).  In 2016, Porcelli et al.(175), also showed that following 6 days of a high 341 
nitrate diet (8.2mmol/day) in healthy males (VO2max 41.2 ± 4.7 ml/kg-1/min-1) there 342 
was a significant improvement in peak power during repeated sprint ability test in the 343 
final 3 of 5 bouts when compared to a control diet. Improvements in mean power 344 
during repeated sprints have also been demonstrated in team sport athletes (VO2max 345 
58 ± 8 ml/kg-1/min-1) in short duration intervals 24 x 6s with short recovery, but not 346 
long 7 x 30s and 6 x 60s with an extended recovery(242). 347 
 Recently, Thompson et al.(222), sought to exploit the enhanced conversion of 348 
nitrite to NO in low oxygen conditions by combining sprint interval training with nitrate 349 
supplementation.  They reported an increase in proportion of type I and type IIa 350 
muscle fibers (Pre:93 ± 8%, Post: 96 ± 6%), highlighting the potential of nitrate to 351 
influence training adaptations in a positive oxidative fiber-type switching manner. 352 
Roberts et al.(189), generated similar findings using an in vitro model, whereby 353 
nitrate increased the proportion of type I and IIa oxidative fibers.  They also found in 354 
animals and humans that both nitrate and exercise training can stimulate PGC1α-355 
mediated, γ-aminobutyric acid secretion from the muscle. 356 
 357 
Administration and Variability of Inorganic Nitrate Supplementation 358 
The use of inorganic nitrate supplementation to increase the bioavailability of 359 
NO in exercise studies has been achieved mainly through the use of concentrated 360 
beetroot juice (approximately 3/4 of studies)(144) .  This supplementation allows for 361 
easy oral administration and a controlled dosage.  To date the results of these 362 
studies have been mixed.  While some studies focused on submaximal exercise 363 
variables as the primary outcome, including both acute and chronic supplementation 364 
regimens, have shown positive effects (20, 43, 125, 130, 152, 176, 223, 228, 245) 365 
many have also shown no significant benefit (25, 31, 115, 193).  Similarly, in studies 366 
employing incremental exercise tests or time trial approaches (which require 367 
maximal efforts) the results are similarly mixed between positive effects (20, 43, 124, 368 
125, 129, 168), and no significant benefit (24, 25, 45, 152, 167, 193, 238).  Excellent 369 
reviews detailing the specifics of individual studies in detail have been published 370 
previously (17, 104, 105). 371 
The reasons for divergent findings are not entirely clear, but it is evident that 372 
numerous factors may influence and regulate physiological responses to inorganic 373 
dietary nitrate.  For example, several studies have shown that the extent of the 374 
increase in plasma nitrite correlates with improvements in parameters of exercise 375 
tolerance and performance(221, 238, 244).  This suggests that factors which 376 
optimise conversion of an oral inorganic nitrate dose may be important.  377 
As outlined earlier in this text, the function of oral commensal bacteria has 378 
been shown to be essential for conversion of nitrate to nitrite.  This process occurs 379 
through the utilization of nitrate as a terminal respiratory electron acceptor by 380 
bacteria under anaerobic conditions.  Oral nitrate reduction appears to occur mainly 381 
on the dorsal surface of the tongue and is  predominantly mediated via two broad 382 
categories of bacteria; the strict anaerobes Veillonella spp, and the facultative 383 
anaerobes Actinomyces spp(58).  In a subsequent study, which combined 384 
metagenomics and biochemical techniques, Veillonella was again the most abundant 385 
nitrate-reducing genus detected though Prevotella, Neisseria, and Haemophilus 386 
were found at a higher abundance than Actinomyces(97)  Other bacteria have also 387 
been identified which may play supporting or inhibiting roles in these processes.  The 388 
current literature limits our ability to draw far-reaching conclusions about the 389 
importance of the specific species and abundance of nitrate-reducing bacteria in the 390 
oral cavity on the conversion of inorganic nitrate to plasma nitrite.  However, studies 391 
which have eradicated or inhibited these bacteria via the use of anti-septic and anti-392 
bacterial mouthwash treatments have been shown to reduce salivary and plasma 393 
nitrite increases and lead to increases systemic blood pressure(77, 111, 240).   394 
A second contributing factor in the variability of the plasma nitrite 395 
concentration responses following oral inorganic nitrate supplementation involves 396 
differences in the vehicle of administration, nitrate dosage and the number of days of 397 
supplementation.  A recent crossover study in 10 healthy males, showed that an 398 
acute dosage of 4.2, 8.4 and 16.8mmol inorganic nitrate (via beetroot juice) 399 
increased plasma nitrite in a dose-dependent manner with peak concentrations 400 
occurring at approximately 2-3 hours post consumption(244).  Interestingly, the 401 
oxygen cost of moderate-intensity cycling was increased relative to dosage but there 402 
was no additional benefit to severe-intensity cycle exercise above 8mmol.  Peak 403 
reductions in blood pressure also occurred at 8.4mmol dosage.  This suggests a 404 
threshold of at least 8.4mmol may be required to realise exercise benefits.   405 
Comparisons between acute versus chronic dosing of inorganic nitrate 406 
suggest that chronic dosing (15 days) may help maintain exercise economy 407 
benefits(228) but can potentially have a greater effect on peak power output and 408 
time trial performance benefits(25, 228).  A recent systematic review and meta-409 
analysis on endurance exercise performance showed a positive trend toward 410 
improvements in time to exhaustion (TTE) when utilising chronic nitrate 411 
supplementation(144).  It has also been reported that longer-term nitrate 412 
supplementation (5-7 days) can result in changes in mitochondrial(127) and 413 
contractile(89) proteins that would be expected to enhance skeletal muscle 414 
metabolic and mechanical efficiency. It would seem unlikely that these changes 415 
could be fully effected within a few hours of nitrate ingestion and therefore the 416 
duration of nitrate supplementation is likely to introduce variability into the potential 417 
efficacy of nitrate on the physiological responses to exercise.  Overall, these findings 418 
suggest at least 5 days of supplementation may be optimal to realise exercise 419 
benefits. 420 
A third contributor to outcome variability is the training status or fitness level of 421 
an individual (40, 106, 176).  Among well trained subjects, there appears to be a lack 422 
of effect of nitrate supplementation (acute or chronic) on exercise performance and 423 
efficiency(25, 45, 123, 167, 238).  Porcelli et al.,(176), found that 6 days sodium 424 
nitrate supplementation (5.5mmol) resulted in a reduction in oxygen cost during 425 
sub-maximal exercise and improved 3km running time trial in individuals with low 426 
fitness level (VO2max: 38 mL/min/kg) but not a high fitness level (VO2max: 72 427 
mL/min/kg).  There was a strong correlation between changes in plasma nitrite and 428 
changes in exercise performance.  Carriker et al.(40), found similar results when 429 
they compared the effects of 4 days of nitrate supplementation (6.2mmol/day) on 430 
treadmill running at intensities of 45, 60, 70, 80, and 85% VO2max.  Low fitness 431 
individuals (VO2max: 42.4 ± 3.2 mL/min/kg) showed a reduction in oxygen cost at 432 
intensities of 45 and 60% of maximal, but there was no difference for the high fitness 433 
subjects (VO2max: 60.1 ± 4.6 mL/min/kg).  The reasons for the potential 434 
ineffectiveness of inorganic nitrate supplementation in athletes could be several-fold.   435 
Perhaps they have specialized diets that already contain high levels of nitrate(123) .  436 
There may also be a high inter-subject variability in the conversion of nitrate to nitrite, 437 
or nitrite to various NO-signalling species.  Another possibility is that eNOS activity is 438 
already maximized in athletes and endothelial NO production is strongly associated 439 
with exercise performance(180, 224).  440 
In summary, the response to dietary nitrate supplementation on exercise 441 
parameters appears to be highly variable both between studies and between 442 
individual participants.  The majority of the studies undertaken have small sample 443 
sizes (n<15), which may be a contributing factor to the sometimes-conflicting results.  444 
Further studies are required with a focus on the sources and mechanisms by which 445 
this variability occurs and how it can be minimized.   446 
Currently, it appears that nitrate supplementation in individuals of a high 447 
training status results in minimal positive benefits.  Additionally, nitrate 448 
supplementation appears to have the greatest chance of benefit when given for a 449 
prolonged period of time (>5 days) at a dosage above 8mmol per day and the 450 
exercise is of a high intensity (relative to the individual), that relies predominantly on 451 
type II muscle fiber activation.  These conditions may best lead to adequate plasma 452 
(and potentially tissue) nitrite concentrations coupled with low PO2 and high H+ 453 
concentrations in the skeletal muscle, creating an ideal environment for the reduction 454 
of nitrite to NO.  The effects of inorganic nitrate supplementation on long term 455 
training adaptations as part of a chronic exercise regimen is currently not known. 456 
 457 
Inorganic Nitrate Supplementation and Exercise in Hypoxia 458 
Given the reduction of nitrite to NO in hypoxic and acidic conditions, an 459 
innovative way to test the ergogenic effects of inorganic nitrate supplementation is by 460 
a reduction in the pulmonary oxygen supply.  Interest in this area was stimulated by 461 
studies of humans indigenous to high-altitude environments.  In 2007, Erzurum et al. 462 
(63), showed that native Tibetans who reside at 4,200m, offset physiological hypoxia 463 
and achieve normal tissue oxygen delivery by means of higher blood flow, enabled 464 
by higher levels of bioactive forms of NO.  The authors suggested this was due to 465 
increased eNOS production, which has been shown to be impaired with increasing 466 
altitude in native lowlanders (59).  Interestingly, circulating nitrogen species, 467 
including nitrate and nitrite, seem to increase as part of the altitude acclimatization 468 
process and those individuals with the highest levels of S-nitrosohemoglobin were 469 
able to walk the furthest in a six-minute walk test(101).  Subsequent studies then 470 
confirmed that dietary nitrate supplementation may hold promise as a prophylactic 471 
for acute altitude sickness(88). 472 
 In a laboratory setting, several studies have shown that dietary nitrate has the 473 
potential to minimize the ergolytic effect of hypoxia on exercise capacity(115, 141, 474 
151, 229).  In 2011, Vanhatalo et al.(229), demonstrated that an acute dose of 475 
dietary nitrate via beetroot juice (~9.3mmol) during the 24hour run up to testing 476 
improved time to exhaustion during maximal knee-extension exercise by ~21% while 477 
breathing reduced oxygen air (FiO2 14.5%).  These improvements were attributed to 478 
reduced muscle perturbations related to fatigue.  At lower oxygen conditions (FiO2 479 
11%), Masschelein et al. showed that a chronic dose of beetroot juice (6 days ~5 480 
mmol/day nitrate) improved exercise efficiency via lower VO2 uptake during 481 
submaximal exercise (~45% VO2peak) and increased overall exercise tolerance(141).  482 
This and a second recent study suggest improvements in skeletal muscle tissue 483 
oxygenation, measured via near-infrared spectroscopy, may be mediators of this 484 
benefit(141, 198).  In more applied conditions, acute beetroot juice supplementation 485 
(~5mmol nitrate) reduced submaximal VO2 and improved 16km cycle race time when 486 
performed breathing FiO2 of 15%(151).   487 
 Interestingly, similar to the data in normoxia, nitrate supplementation appears 488 
to be less effective for increasing exercise efficiency or performance in hypoxic 489 
conditions when ingested by well-trained athletes(13, 28, 136).  For example, in well-490 
trained individuals (VO2max>65ml/kg/min) there were no changes in exercise 491 
economy or endurance in a simulated 10km cycling time trial following a single 492 
~6.5mmol dose (beetroot juice) 2 hours before testing at FiO2~15%(136).  Similarly, 493 
despite having a longer supplementation period (3 days ~7mmol/day oral sodium 494 
nitrate) there were no improvements in time to completion of a 15km cycle time trial 495 
at FiO2~11% of the inspired air(28). 496 
 Overall, in low oxygen conditions, such as at altitude, inorganic nitrite 497 
supplementation appears to hold promise as prophylactic.  In fact, it has even been 498 
suggested that hypoxic conditions may be optimal to reveal ergogenic benefits of 499 
dietary nitrate supplementation(115).  However, nitrate’s role in short term hypoxic 500 
exposures in highly trained athletes appears limited.  This suggests nitrate 501 
supplementation is most effective in conditions of low tissue oxygenation when 502 
coupled with dysfunctional cellular metabolism, such as what is seen in patients with 503 
chronic cardiovascular disease. 504 
 505 
Cardiovascular Disease and Exercise 506 
Patients with CVD usually experience significant levels of disability due to a 507 
reduction in exercise capacity and a loss of physical function.  This results in a lower 508 
quality of life and increased morbidity and mortality.  In many populations with CVD, 509 
despite differences in disease aetiologies, exercise capacity, in the form VO2peak, is a 510 
strong independent predictor of survival(158).  For example, patients with PAD are 511 
primarily limited by leg claudication pain whereas those with chronic heart failure 512 
(CHF) suffer from dyspnoea and fatigue.  In both cases, the end result is 30-55% 513 
lower VO2peak than their healthy counterparts(14, 82). 514 
Conversely, even modest improvements in exercise tolerance have been 515 
shown to lower all cause-mortality and morbidity in these individuals.  For example, a 516 
~6% improvement in VO2peak reduced all-cause morbidity and mortality in CHF by 517 
5%(53, 217).  Additionally, data from a widely used six-minute walk test, which may 518 
better represent a measure daily function(142), shows that an improvement of just 519 
45 meters is deemed to be a clinically meaningful change in patients with CHF(207). 520 
The relationship between exercise capacity and physical function and health 521 
outcomes has led to a plethora of exercise based studies in clinical CVD 522 
populations.  However, the burden of exercise participation for individuals with CVD 523 
may be increased due to numerous peripheral tissue maladaptations borne of 524 
chronic under-perfusion and underuse.  Peripheral tissue abnormalities common to 525 
multiple chronic CVD disease states are shown in figure 2 and include endothelial 526 
dysfunction/reduced NO bioavailability(199, 201), capillary density rarefaction(14, 527 
119, 188), and skeletal muscle hypo-perfusion(78, 216), increased reactive oxygen 528 
species(1, 191, 237) and inflammation(109), increased insulin resistance, 529 
mitochondrial dysfunction(190), reduced aerobic enzyme activity(215), and a 530 
preferential loss of type I oxidative fibers(119).  Overall this results in patients 531 
exhibiting a glycolytic phenotype which, in addition to any central cardiovascular 532 
limitations, promotes the early onset of fatigue and exercise intolerance.  In turn, this 533 
may contribute to an increased burden of exercise participation for these individuals, 534 
ultimately leading to higher recidivism rates in training regimens. 535 
Inorganic nitrate supplementation has been shown to play a key role in 536 
exercise capacity in numerous studies in healthy subjects (as previously illustrated). 537 
The intent in this cohort is to use nitrate supplementation as an “ergogenic” to 538 
augment “normal” levels of bioavailable NO in exercising tissues in order to enhance 539 
physical performance, stamina or recovery.  Supplementation within the clinical 540 
cohort, however, takes a “therapeutic” approach with the aim of restoring deficient 541 
NO bioavailability, correcting physiological dysfunctions, and recovering exercise 542 
capacity/performance and health. 543 
In this section, we will build on the data presented in healthy supplementation 544 
studies and focus on known physiological maladaptations that reduce exercise 545 
tolerance in individuals with PAD, CHF, and Type II Diabetes Mellitus (T2DM).  We 546 
will highlight the potential mechanisms by which inorganic nitrate consumption, and 547 
the associated increase in circulating nitrite and NO bioavailability, may act as a 548 
therapeutic to attenuate these dysfunctions and increase exercise tolerance. 549 
 550 
Inorganic Nitrate Supplementation and Exercise Performance in Peripheral Arterial 551 
Disease 552 
Peripheral artery disease is caused by atherosclerotic plaque formation in the 553 
large arteries of the legs, resulting in reduced blood flow to the lower extremities(9).  554 
It is estimated that the worldwide prevalence of PAD has increased by 23.5% in the 555 
last decade and now affects 202 million people(68).  Intermittent claudication (IC) is 556 
the major clinical manifestation of PAD and occurs when arterial occlusive disease 557 
reduces blood flow to the peripheral vasculature during exercise.  Among subjects 558 
with intermittent claudication from PAD, 1/3rd have pain during light activity at home 559 
and an additional 1/3rd have pain walking a short distance (one block)(91).  These 560 
patients suffer from a markedly impaired quality of life and a high perception of 561 
disability(161). Increased pain free walking capacity is a primary goal of therapy for 562 
patients with PAD. 563 
Although measures of conduit vessel and gross limb blood flow, such as ankle 564 
brachial systolic blood pressure index (ABI), are used to diagnose PAD, they show a 565 
poor relationship with functional capacity(29, 92, 93, 138, 171, 248).  Additionally, 566 
surgical revascularization, which improves blood flow, does not normalize exercise 567 
performance(183) and conversely exercise performance can be increased without 568 
changes in conduit vessel hemodynamics(153, 154, 210). 569 
It appears that the key to increasing functionality in patients with IC may lie at 570 
the resistance arteries, arterioles and capillaries that serve the skeletal muscle tissue 571 
distal to the site of stenosis.  These are the vessels which are responsible for much 572 
of the oxygen delivery(225) and become hypoxic during the increased demands for 573 
perfusion accompanying physical exertion.  Therefore, inorganic nitrate 574 
supplementation may be a novel intervention to improve oxygenation to these areas 575 
of skeletal muscle ischemia and increase physical function.  This would be a 576 
significant step forward in the treatment of PAD. 577 
In 2010, our group(7) demonstrated increases in time to claudication onset 578 
pain (66%) and peak walking time (52%) in subjects with PAD following three 579 
months of supervised exercise training.  The strongest independent predictor of 580 
these changes was the ability to increase plasma nitrite concentrations during 581 
maximal exercise, which was most likely as a result of an increase in endothelial NO 582 
production.  In a follow-up repeated measures crossover study, we orally 583 
administered 500ml of beetroot juice containing 9mmol nitrate (compared to an 584 
orange juice placebo) in 8 subjects (4 male, 4 female) age 67+13years with IC (ABI 585 
in the incident leg of 0.64+0.2).  The results of a maximal graded treadmill test 586 
(Gardner protocol) showed an increase in average exercise time before the subject 587 
reported the onset of claudication pain (COT) of 18% (32sec), and an increase in 588 
maximal walking time of 17% (65sec) respectively(116).  This is a clinically 589 
meaningful and statistically significant increase for a disease state characterized by 590 
reduced physical function and quality of life(170, 207).  Additionally, there were no 591 
changes in ABI or endothelial function, suggesting no increase in endogenous 592 
vascular NO production.  The increases in performance were accompanied by a 593 
reduction in fractional oxygen extraction at the working tissues, measured by near 594 
infra-red spectroscopy (NIRS) suggesting increased perfusion to working tissues.   595 
Currently, there are two clinical trials listed as in progress on clinical trials.gov 596 
investigating the effects supplementation of either beetroot juice (NCT02553733) or 597 
Neo 40 (a tablet containing beetroot powder, L-citrulline and sodium nitrite) 598 
(NCT02934438) on walking performance in PAD, but there are no other results that 599 
we are aware of at the time of submission. 600 
Studies in animal models of PAD are also promising with a dose dependent 601 
relationship between nitrite dose (via intraperitoneal injection twice daily for 7 days) 602 
and improved tissue perfusion via angiogenesis in a murine model with permanent 603 
femoral artery ligation of the hind limb(121).  Co-administration of the NO scavenger 604 
carboxy-PTIO with the nitrite completely abrogated the increase in perfusion 605 
suggesting the mechanism of effect is NO mediated.  606 
 While it is premature to speculate on overall clinical utility of a nitrate based 607 
therapy for peripheral artery disease, the early data appears encouraging.  Additional 608 
large clinical trials and basic science studies are required to determine important 609 
molecular mediators conveying beneficial effects of nitrite therapy during specific 610 
disease states. 611 
 612 
Inorganic Nitrate Supplementation and Exercise Performance in Chronic Heart 613 
Failure 614 
Chronic heart failure is characterised by the inability of the heart to pump 615 
sufficient blood to meet the body’s metabolic needs. It affects approximately 23 616 
million people worldwide with a direct cost of $36 billion per year in the U.S. 617 
alone(131).  While there are unique aetiologies associated with the development of 618 
CHF, the hallmark symptom experienced by patients is exercise intolerance.  In 619 
comparison to healthy controls, patients with CHF have significantly lower VO2peak 620 
(~50% reduction) with accompanying reductions in cardiac output by 52-53% 621 
during maximal exercise(57, 82, 214). As exercise capacity (and in particular 622 
VO2peak) is a strong independent predictor of mortality and morbidity in patients 623 
with CHF, targeting this deficit is of clinical importance(12, 137).  Endothelial 624 
dysfunction and reduced NO bioavailability have been linked to both the initiation 625 
and progression of CHF(140). More specifically, imbalances in the production and 626 
utilization of NO contribute to the elevated cardiac filling pressures, symptoms of 627 
dyspneoa, the severity of the disease, and the functional capacity of the 628 
patient(145, 200) 629 
It was historically assumed that this inability to augment cardiac output 630 
during exercise (central dysfunction) was the main contributor to the exercise 631 
intolerance experienced by patients with CHF(173).  However, more recently, 632 
maladaptation’s within the peripheral tissues (secondary to the initial central 633 
dysfunction) have been highlighted as crucial limiters in exercise capacity.  634 
Chronic peripheral tissue under perfusion (due to reduced cardiac output) results 635 
in capillary density rarefaction, decreased mitochondrial function and a preferential 636 
loss of type I oxidative fibres, which cumulatively shift individuals with CHF to a 637 
more glycolytic phenotype(47, 61, 172, 215, 216, 239).  These conditions are ideal 638 
for inorganic nitrate targeted therapeutics. 639 
CHF is not a single uniform state, but rather a multifarious syndrome that 640 
presents generally as one of two classifications depending on whether the patient 641 
has a preserved ejection fraction (HFpEF) or a reduced ejection fraction 642 
(HFrEF)(36). There are key etiological characteristics that differentiate the two 643 
classes.  HFrEF often has a sudden onset following a myocardial infarction 644 
whereas patients with HFpEF are typically older, more commonly female, and 645 
usually have multiple comorbidities associated with a slower onset(122).  Patients 646 
with HFrEF characteristically present with reduced cardiac output (Q) at rest and 647 
during exercise. Patients with HFpEF usually have a normal resting Q but exhibit 648 
increased left ventricular (LV) filling pressures which become pronounced under 649 
stress(182), and are associated with exertional dyspnoea and reduced exercise 650 
cardiac output (16, 57).  Despite the heterogeneity of the two classes of CHF, the 651 
growing body of literature suggests that nitrate supplementation remains 652 
potentially efficacious in both syndromes.  653 
 654 
a) HFpEF studies 655 
Interestingly studies of inorganic nitrate supplementation in patients with 656 
HFpEF have shown more positive outcomes than those in HFrEF(62, 246, 247). 657 
There are two potential explanations for these findings. First, peripheral under-658 
perfusion and an inability to extract oxygen at the tissue level has been found to be 659 
more significant in patients with HFpEF, as evidenced by significantly lower a-660 
vO2diff during exercise than both HFrEF and controls(57).  Second, a recent study 661 
by Borlaug et al.(27) has demonstrated that a sodium nitrite infusion in patients 662 
with HFpEF significantly reduced LV filling pressures during exercise. While the 663 
focus of this review is on natural product supplementation, these mechanistic 664 
benefits from nitrate/nitrite products lend promise to the use of similar more natural 665 
options. 666 
In 2015, Zamani et al.(246), used a single dose of beetroot juice (12.9mmol 667 
nitrate), in 17 patients with HFpEF.  They showed significant improvements in 668 
VO2peak and time to exhaustion (TTE) during a maximal exercise test. The authors 669 
postulated that the beneficial changes in exercise capacity were due to an 670 
accompanying decrease in systemic vascular resistance, thus reducing afterload and 671 
increasing Q. Surprisingly, they showed no improvements to exercise efficiency, 672 
suggesting nitrate may have differential effects on the mitochondrial function in 673 
aging/diseased populations when compared to healthy individuals (as described 674 
previously).  675 
Similarly, in 2016, Eggebeen et al.(62), used beetroot juice to examine the 676 
effects of both a single dose (6.1mmol) and 1 week dosing (6.1mmol/day) to 677 
determine the effects of nitrate supplementation in HFpEF during a submaximal 678 
cycling endurance exercise bout (at 75% of measure maximal power). They found no 679 
significant benefits in exercise performance with acute supplementation, but the 680 
chronic dosing elicited a 24% increase in TTE.  Their data also suggested that the 681 
improvements were likely due to decreases in systemic vascular resistance (SVR) 682 
(62).  To complement these findings, other mechanistic studies utilizing infusions or 683 
nebulized inorganic sodium nitrite have demonstrated improvements in SVR (26, 684 
27).  Significantly, Borlaug et al.(27), noted that the improvements in cardiac function 685 
following nitrite ingestion were actually more pronounced during exercise, again 686 
supporting nitrite’s preferential effects in low oxygen environments and its potential 687 
utility as a targeted approach to treating HFpEF. 688 
A second, more recent study by Zamani et al.(247), utilizing a high chronic 689 
dose of potassium nitrate (6mmol/day for 1 week, increasing to 18mmol per day for 690 
the second week) also found significant improvements in TTE as well as decreases 691 
in CHF symptoms (via the Kansas City Cardiomyopathy Questionnaire). While they 692 
did not assess muscle fibre composition or recruitment, the authors suggested that 693 
the maximal exercise approach employed during testing may provide preferential 694 
conditions to optimise the benefits of inorganic nitrate supplementation (hypoxia and 695 
greater type II fibre recruitment).  696 
In an effort to discover if nitrate supplementation may have an additive 697 
beneficial effect on physical function when consumed in conjunction with exercise 698 
training, Shaltout et al.(197), recently gave beetroot juice (6.1mmol nitrate) plus 699 
exercise training for 3 days per week for 4 weeks versus exercise alone.  While, as 700 
expected, they saw significant improvements in aerobic capacity in both groups, the 701 
nitrate did not have a significant additive benefit. However, given the sample size 702 
was small for a study using an exercise comparison group (exercise alone elicits 703 
relative large benefit), a short treatment period, and a low dosage regimen, this 704 
additive approach may be worth of greater exploration.   705 
 706 
b) HFrEF studies 707 
Patients with HFrEF usually demonstrate reductions in Q at both rest and 708 
during exercise(57, 64) and chronotropic incompetence (the inability to sufficiently 709 
augment HR during exercise) substantially contributes to the reductions in VO2peak.  710 
Interestingly (and in contrast to HFpEF) peripheral oxygen extraction during 711 
exercise (a-VO2diff) appears to remain similar to that of healthy cohorts(35, 57).  712 
However, they still demonstrate skeletal muscle abnormalities that contribute to 713 
exercise intolerance(46, 118, 230).  The potential therapeutic benefits of 714 
nitrate/nitrite interventions were highlighted by a recent study in HFrEF rats.  Glean 715 
et al.(76), demonstrated that a single dose of sodium nitrate lead to significant 716 
elevation (10%) in vascular conductance within the hind limb skeletal muscles. 717 
Moreover, the hind limb skeletal muscles that showed increases in vascular 718 
conductance and blood flow following dosing were primarily comprised of (63%) 719 
type IIb + IId/x fast twitch fibers.  This further supports nitrate/nitrite’s potential as 720 
particularly effective intervention for those individuals known to be more type II 721 
fiber dominant, as is the case for patients with CHF. 722 
Unfortunately, to date there is only one study of exercise capacity in 723 
individuals with HFrEF, following nitrate supplementation.  In an elegantly designed 724 
cross-over study, Hirai et al., found that 9 days of beetroot juice supplementation 725 
(12.1mmol/day) did not result in any improvements in exercise tolerance (TTE or 726 
VO2peak).  They also saw no significant changes in central hemodynamics, skeletal 727 
muscle oxygenation, or the oxygen cost of exercise(94).  The authors suggest the 728 
negative findings could be due to the aforementioned relatively normal peripheral 729 
oxygen extraction in comparison to HFpEF.  However, future studies in this cohort 730 
are warranted and should aim to optimize both the dosing amount and duration.  731 
There has been a second study in patients with HFrEF but this examined isokinetic 732 
knee extensor power in isolation(49).  They showed that a single dose of inorganic 733 
nitrate (11.2mmol) via beetroot juice, improved maximal power output by 13%, which 734 
is much larger than the 6% increase observed in healthy controls following nitrate 735 
supplementation. They proposed the response was mediated by NO’s known 736 
stimulation of guanyl cyclase which increases c-GMP levels. As activation of c-GMP 737 
increases max power, especially in type II fibers, this type of intervention could be 738 
particularly efficacious in CHF where the fast-twitch fibres are more readily recruited 739 
(234). 740 
 It is clear that inorganic nitrate supplementation holds a good deal of promise 741 
in patients with CHF.  To date, results are predominantly in support of an exercise 742 
benefit in patients with HFpEF, which is logical given our understanding of nitrates 743 
mechanism of action in the peripheral tissues and the greater deficits in a-vO2diff in 744 
HFpEF.  However, patients with HFrEF are currently understudied and as of yet 745 
there is no direct comparison of HFpEF and HFrEF in the same study design to 746 
provide an accurate assessment of any differential benefits of inorganic nitrate 747 
supplementation between the two classifications. 748 
 749 
Inorganic Nitrate Supplementation and Exercise Performance in Diabetes Mellitus 750 
The incidence of diabetes mellitus has quadrupled since 1980, from 108 to 751 
422 million people(241).  Despite medical treatment diabetics die approximately 5-10 752 
years earlier than non-diabetics, with approximately 50% of deaths being attributed 753 
to cardiovascular disease(69, 150).  Regular participation in physical activity (along 754 
with diet and pharmacotherapy) is a cornerstone of the treatment forT2DM(51, 98). 755 
Exercise has been shown to increase insulin sensitivity, glucose uptake, and reduce 756 
cardiovascular morbidity. However, the burden of exercise participation for 757 
individuals with T2DM appears to be increased due to several skeletal muscle tissue 758 
maladaptations(78, 114, 159, 163, 164).  The function of skeletal muscle is of 759 
particular importance for individuals with T2DM given that it is responsible for 760 
approximately 80% of whole body glucose uptake following hyperinsulinemia and 761 
exercise(55). The increase in glucose uptake is correlated closely with increase in 762 
blood flow (approx. nine-fold) in the exercising muscle(55).  763 
Individuals with T2DM appear to have several defects in NO production and 764 
transport that could contribute to exercise intolerance and to a decline in 765 
cardiovascular health. One study showed that impaired endothelial production of NO 766 
during acute exercise stress in subjects with T2DM was the strongest predictor of 767 
exercise intolerance, in a multivariate regression model(3). The ability to conserve 768 
and transport NO via the plasma and red blood cells (RBC) (as described in an 769 
earlier section) may be dysfunctional in individuals with diabetes(99, 147, 212).  One 770 
mechanism outlined for this deficiency is the preferential binding of NO to 771 
glycosylated RBC’s and decrease in disassociation with changes in PO2. Ultimately 772 
this results in decreased NO bioavailability in the microvasculature as well as 773 
reductions in NO and O2 delivery to peripheral tissues. Furthermore, individuals with 774 
T2DM have a number of other pathologies that may cause inactivation of NO, for 775 
instance, an increase in superoxide production which interacts with NO to produce 776 
peroxynitrite(80, 149). 777 
Compared to patients with PAD, those with concomitant T2DM failed to 778 
increase endogenous vascular NO production and exercise capacity following 3 779 
months of supervised exercise training(8).  This suggests the possibility that they are 780 
less able to increase endogenous endothelial NO production which may be reflected 781 
in reduced plasma nitrite concentration following exercise and reduced hyperaemic 782 
response following ischemic stimuli(5, 120).  783 
Patients with T2DM present several potential therapeutic opportunities for 784 
dietary nitrate supplementation to improve their metabolic and cardiovascular health. 785 
In animal models, it has been demonstrated that NO bioavailability influences 786 
several aspects of glucose-insulin homeostasis including regulation of mitochondrial 787 
function, insulin secretion, glucose uptake and blood flow(39, 90, 103, 160, 169). 788 
The seminal work by Carlstrom and colleagues(39), demonstrated that eNOS 789 
deficient mice with several of key features of diabetes, benefitted from chronic nitrate 790 
supplementation. Restoring NO bioavailability resulted in improvements in glucose 791 
tolerance, glycosylated haemoglobin, fasting glucose, and circulating triglycerides.  792 
These findings have subsequently been reproduced and further investigated by 793 
several others(103, 160, 169, 208). From a mechanistic perspective, nitrate or nitrite 794 
supplementation results in an increase in glucose uptake by increased GLUT4 795 
translocation via AMPK pathway(56, 103), similar to the pathways activated by 796 
exercise(186). Collectively, these animal models provide an in-depth investigation 797 
into the promising metabolic benefits of nitrate or nitrite supplementation for 798 
metabolic conditions, in particular T2DM. However, to date, no studies in animal 799 
models have assessed the effects of nitrate supplementation on exercise in T2DM.  800 
Unfortunately, positive metabolic findings from animal models have failed to 801 
translate into humans with T2DM.  This is despite acute and chronic nitrate 802 
supplementation studies producing significant increases in plasma nitrite(44, 74, 803 
202).  Cermak et al(44). showed no differences in an oral glucose tolerance test, 804 
following single dose sodium nitrate (~10.5mmol) and Shepherd et al.(202), failed to 805 
observe changes in the oxygen cost of exercise or exercise tolerance following 4 806 
days of beetroot juice (6.43mmol/day).  In a longer period of supplementation, two 807 
weeks of nitrate (7.5mmol/day) where the median plasma nitrite reached 390 nM, 808 
Gilchrist and colleagues(74), found no effects on endothelial function or insulin 809 
sensitivity. 810 
Possible explanations for the lack of physiological changes following nitrate 811 
supplementation in humans include the aforementioned defects in NO production 812 
and transport. Additionally, the duration of diabetes may be much longer in human 813 
patients compared to in animal studies and possibly most significantly, there could 814 
be interference effects from diabetic medications.  For instance, metformin, the most 815 
prescribed first-line medication for diabetics (used to lower blood glucose), may 816 
interfere with beneficial effects of dietary nitrate on aspects of exercise related 817 
parameters. A mechanism of action for increased glucose uptake via metformin 818 
involves the non-competitive inhibition of the skeletal muscle mitochondrial electron 819 
transport chain at complex 1. This causes a decrease in mitochondrial respiration, 820 
mitochondrial dysfunction and a decreased ATP production(33, 235), which although 821 
beneficial for glucose uptake, produces a negative effect on muscle function and a 822 
reduction in exercise capacity(30, 166).  This is in contrast to the role that nitrite 823 
alone may play on the efficiency of mitochondrial respiration in both human whole 824 
body and isolated muscle fiber experiments (as described earlier).  Additionally, 825 
nitrite exhibits beneficial effects in normoxia for glucose uptake via mitochondrial 826 
fusion activation of protein kinase A(110, 117).  For further information on this area 827 
see: (79, 203).  This mechanism may be especially pertinent in T2DM where tissue 828 
perfusion is reduced during exercise and a glycolytic phenotype dominates in the 829 
skeletal muscle.  830 
Given that only one study has assessed this (and only at a relatively low 831 
exercise intensity using the 6-minute walk), future studies may wish to further 832 
examine the effects of longer term supplementation on exercise. These studies 833 
should also aim to target individuals who are newly diagnosed or who have 834 
prediabetes.   835 
 836 
Conclusion 837 
In summary, over the last 10 years there has been tremendous growth of 838 
interest in the role of inorganic nitrate supplementation, especially in the form of 839 
beetroot juice, on exercise performance.  The majority of the studies have been 840 
focused on healthy populations with mixed results.  Much of the variation may be 841 
attributed to small sample sizes and differences in dosing regimens.   842 
It appears that a chronic dosing strategy, consisting of ~8mmol per day, for at 843 
least 5 days provides the greatest likelihood of achieving plasma nitrite 844 
concentrations greater than 400nM and a subsequent ergogenic benefit.  However, 845 
at this time there is demonstrated within and between subject variability in the 846 
conversion of nitrate to nitrite, as well as in the physical function benefits following 847 
treatment.  This has led to the potential of individuals being classed as “responders” 848 
or “non-responders” within an otherwise homogeneous sample. This is a current 849 
area of intense research, with investigations into the role of the oral and gut 850 
microbiome or particular interest.   851 
It appears that nitrate supplementation in individuals with a high training 852 
status in lower intensity aerobic-type activities, has a low chance of positive results. 853 
Elite athletes are well adapted to maintain adequate microvascular perfusion and 854 
match oxygen delivery to the increased requirements of the working muscle during 855 
the majority of exercise conditions. Thus, it is logical that there would be mixed 856 
results following nitrate supplementation when we consider that nitrite is 857 
preferentially reduced to NO in conditions of low PO2 and low pH.  It also provides a 858 
potential explanation for why high-intensity activities that rely predominantly on fast –859 
twitch muscle fibers have shown the greatest potential for an ergogenic benefit in 860 
healthy, trained individuals. 861 
Along the same lines, patients with CVD develop multiple peripheral tissue 862 
abnormalities, often as a maladaptation to chronic under perfusion, which result in an 863 
overall glycolytic phenotype.  This, coupled with endothelial dysfunction (an inability 864 
to endogenously upregulate NO) and increased NO scavenging, make nitrate 865 
supplementation a particularly promising intervention for patients with CVD. This 866 
theory is supported by encouraging data showing restorative effects on time to 867 
claudication pain onset and peak walk times in PAD as well as muscle contractile 868 
function and exercise performance in patients with CHF.  Interestingly, to date no 869 
benefits in exercise performance following inorganic nitrate supplementation have 870 
been shown in patients with T2DM, although the role of metformin in mitochondrial 871 
function may be a mitigating factor to be further investigated. 872 
In summary, inorganic nitrate supplementation within the CVD cohort shows 873 
promise as a potential “therapeutic” with the aim of restoring deficient NO 874 
bioavailability, correcting physiological dysfunctions and recovering exercise 875 
capacity/performance and health.  Given the well documented relationship between 876 
reduced exercise capacity with morbidity and mortality it may be an intervention 877 
which provides significant functional and clinical benefits to patients with CVD. 878 
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Figure Legends 1745 
Figure 1: Nitrate-Nitrite-Nitric Oxide Formation/Recycle Pathways.   1746 
In the presence of oxygen endothelial nitric oxide synthase (eNOS) catalyzes the 1747 
oxidation L-arginine to NO.  NO may also be rapidly oxidized to nitrite (NO2-) and 1748 
nitrate (NO3-).  A secondary source of vascular NO is via diet.  Consumption of food 1749 
stuffs high in inorganic nitrate (green leafy vegetables, beetroot) have been shown to 1750 
increase plasma nitrate which can be secreted in saliva and reduced to nitrite by 1751 
commensal bacteria in the mouth.  Nitrite can then be further reduced to NO (and 1752 
other biologically active nitrogen oxides) via several mechanisms which are 1753 
expedited under hypoxic conditions.  Hence, although some of the circulating nitrate 1754 
and nitrite are excreted in the kidneys they are also able to be recycled back to NO 1755 
Adapted from (6) 1756 
 1757 
Figure 2: Peripheral Tissue Maladaptation’s in Cardiovascular Disease Populations 1758 
and Potential Therapeutic benefits of Inorganic Nitrate Supplementation 1759 
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 CHF type Author N Duration Design Dose/Administration Exercise Outcomes 
 
 
 
 
 
HFpEF 
Zamani, 
2015  
17 Acute Double-blind, randomized, 
crossover 
Beetroot Juice-12.9mmol Nitrate No change in maximal exercise efficiency  
Increase in VO2peak (p=0.005)  
Increase in time to exhaustion (p=0.02) 
Eggebeen, 
2016 
18 Acute A:   Cross-over design Beetroot Juice-6.1mmol Nitrate No change in sub-max time to exhaustion 
Chronic  
 
B:  All treated Beetroot Juice 7 days-6.1mmol 
Nitrate 
Increase in sub-maximal time to 
exhaustion (p=0.02) 
Zamani, 
2017 
12 Chronic 
 
Single Blind Potassium Nitrate 7days 12mmol 
followed by  
Potassium Nitrate 7days 18mmol 
No change in VO2peak 
Increase in Time to exhaustion: (p=0.002) 
 
HFrEF 
Hirai, 2017 10 Chronic 
 
 Double-blind, randomized 
crossover  
Beetroot Juice 9 days-12.9mmol 
Nitrate 
No change in exercise performance 
measures 
 
 
